[Immunoglobulin treatment for neonatal hemochromatosis: a case report in a context of immunoglobulin delivery quotas].
Neonatal hemochromatosis is a rare disease characterized by iron deposits in several organs. The natural course leads to lethal liver failure. A preventive treatment was recently introduced: high-dose intravenous immunoglobulins during pregnancy to prevent fetomaternal allo-immunization. Nevertheless, the prescription of massive quantities of immunoglobulins can lead to a drug shortage which the hospital pharmacist must deal with. We report the case of a pregnant woman with high risk of transmitting neonatal hemochromatosis. We discuss the pharmaceutical difficulties encountered when managing patients with a high risk of neonatal hemochromatosis in the context of immunoglobulin shortage with the delivery quotas established by the French National Health Authority. In this context, a national stock would be useful to deal with rare diseases and thus to support hospitals.
Lecointre
R
R
Service de pharmacie, CHU de Saint-Etienne, hôpital Nord, 42055 Saint-Etienne cedex 02, France. lecointre.romain@yahoo.fr
Lima
S
S
Varlet
M-N
MN
Combe
C
C
D000328:Adult; D000075202:Contraindications; D005260:Female; D006432:Hemochromatosis / Q000151:congenital* / Q000188:drug therapy*; D006801:Humans; D007136:Immunoglobulins / Q000009:adverse effects* / Q000627:therapeutic use*; D007231:Infant, Newborn; D011247:Pregnancy
D007136:Immunoglobulins